🔗 Share this article World Health Organization Raises Alert Over Critical Shortage of Obesity Medications Under one in 10 patients who could benefit from weight-loss injections including Wegovy are able to get them, caution the global health agency as it issues its first guidance on the drugs. Given in excess of 1,000,000,000 individuals worldwide now obese, it is calling for increased and just access to GLP-1 medication. According to estimates, over two billion could be obese by 2030 unless action is taken. "Our latest guidelines recognises that excess weight is a chronic disease that can be treated with comprehensive and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and logistical bottlenecks are key barriers to broad availability to the jabs that can aid individuals in losing substantial body mass, says the body. GLP-1 Therapy Supply Crisis Even under the current most favorable scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – under 10% of those who need them, according to the WHO. The recommendation encourages nations and manufacturers to expand availability, by approaches including licensing agreements. Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is due to expire in a number of nations in 2026. The Way Obesity Drugs Work GLP-1 drugs mimick a body's own hormone to reduce digestion speed, reduce hunger and increase satiety so users eat less. Patients typically see weight reduction after several weeks of starting on the regular doses. Evidence indicates patients may regain a significant portion a year later of discontinuing the drug, as their usual food cravings come back. Being carrying excess weight raises your likelihood for contracting diseases, like diabetes, cardiovascular issues, brain attack, and some malignancies. Obesity affects individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.
Under one in 10 patients who could benefit from weight-loss injections including Wegovy are able to get them, caution the global health agency as it issues its first guidance on the drugs. Given in excess of 1,000,000,000 individuals worldwide now obese, it is calling for increased and just access to GLP-1 medication. According to estimates, over two billion could be obese by 2030 unless action is taken. "Our latest guidelines recognises that excess weight is a chronic disease that can be treated with comprehensive and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and logistical bottlenecks are key barriers to broad availability to the jabs that can aid individuals in losing substantial body mass, says the body. GLP-1 Therapy Supply Crisis Even under the current most favorable scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – under 10% of those who need them, according to the WHO. The recommendation encourages nations and manufacturers to expand availability, by approaches including licensing agreements. Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is due to expire in a number of nations in 2026. The Way Obesity Drugs Work GLP-1 drugs mimick a body's own hormone to reduce digestion speed, reduce hunger and increase satiety so users eat less. Patients typically see weight reduction after several weeks of starting on the regular doses. Evidence indicates patients may regain a significant portion a year later of discontinuing the drug, as their usual food cravings come back. Being carrying excess weight raises your likelihood for contracting diseases, like diabetes, cardiovascular issues, brain attack, and some malignancies. Obesity affects individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.